WuXi XDC’s Post

Read your free issue of Nucleic Acid Therapeutics Journal today! ♦️Be prepared to challenge your mind with leading-edge research papers and reviews. ♦️Stay abreast of emerging technologies ♦️Read commentaries on advancements in oligonucleotide science The OTS Official Journal: https://lnkd.in/gfDwMhr #ots #oligotherapeutics #oligonucleotide #biotech #biotechnology #science #research #pharmaceuticals #networking #otsmember #nucleicacidtherapeutics #nucleicacid #otsjournal

Non-canonical building blocks incorporation propels us ahead in the biotechnology landscape. By incorporating unnatural amino acids, we unlock functionalities not available in the natural repertoire, enabling the creation of proteins with new-to-nature properties and activities, but additionally leveraging unnatural amino acids opens up unique opportunities for patenting new proteins and their associated processes. Our focus on unnatural amino acids embodies our commitment to meet the specific needs of our partners. Whether it’s customizing drugs for better patient outcomes or designing enzymes for industrial applications, our tailored approach ensures that we deliver high precision and quality, underscored by groundbreaking science. Hope you enjoy the video about Constructive Bio!

Are you ready to revolutionise your pharmaceutical pipeline with the next generation of precision proteins, ADCs and peptide drugs?  At Constructive Bio, we use non-canonical amino acids to develop groundbreaking designer drugs that surpass the limitations of conventional proteins. Our advanced engineered translation solution optimizes fidelity and functionality for precise and scalable production using biology, offering new strategies to navigate natural liabilities in biologics drug design and manufacturing. Meet us to discover the power, passion, and creativity behind our approach—watch our video below to see how Constructive Bio is pioneering the future of biotechnology. #Bio2024

Are you visiting #BIO2024? 🚀 Meet Physiomics plc’ CEO, Peter Sargent, and Head of Business Development, Hayley Close, and discover how our solutions can accelerate your drug development pipeline. We’re here to help you make informed decisions throughout the drug development lifecycle. Don’t miss the chance to connect with us. Reach out through the partnering system or contact Hayley directly! https://lnkd.in/ejW6ZMYH Biotechnology Innovation Organization #biotech #pharma #drugdevelopment #pkpdmodelling #quantitativepharmacology #mathematicalmodelling

Adalvo's 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐓𝐞𝐚𝐦 is gearing up for the Biotechnology Innovation Organization (𝐁𝐈𝐎) 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐯𝐞𝐧𝐭𝐢𝐨𝐧 in San Diego, California from June 3rd to 6th. Get in touch with our 𝐒𝐕𝐏, 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐋𝐞𝐠𝐚𝐥 𝐀𝐟𝐟𝐚𝐢𝐫𝐬, Arni Baldursson and 𝐃𝐢𝐫𝐞𝐜𝐭𝐨𝐫, 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭, Tarun Chawla to explore partnership opportunities and discuss the latest developments in the pharmaceutical industry. Book your meetings now and stay tuned for live updates from the event. #Adalvo #AlwaysOnTarget #BIO2024

🌍 Together, we can shape the future of biotechnology. ✨ At Ningaloo Biosystems, we are proud to be at the forefront of biopharmaceutical innovation! 🚀 By controlling cells in real-time, we enable the production of therapeutic proteins that are difficult to make. This not only paves the way to more efficient production but can also significantly improve manufacturing economics. How? Learn more at the upcoming 4th Optogenetic Technologies and Applications Conference in Boston, MA, starting on September 10, 2024. #biopharma #NextGenMedicines #optogenetics

🗣️ Meet our facilitator, Firoz Antia 🚀 Get ready to dive deep into the Manufacturing track, at our upcoming Oligonucleotide Therapeutics Xchange 2024, Boston, where we'll tackle the downstream manufacturing challenges for synthetic oligonucleotides: 💥 Chromatography, Desalting, and Isolation 💥 Conjugation 💥 Annealing for Double-Stranded Products 💥 Analytical Characterization 🕰️ Time: 09:05 – 10:05 🗓️ Date: June 21st, 2024 📍 Location: Woburn Hilton Hotel, 2 Forbes Road, Woburn, US 🔑 Reserve your free spot now! https://bit.ly/3wYHLnQ 📢 We're thrilled to have Firoz Antia, Executive Director and Head of Oligonucleotide Development at Biogen, as a facilitator. With over two decades of expertise in drug development, process engineering, and manufacturing, Firoz brings invaluable insights into the latest advancements in oligonucleotide therapeutics. 🎯 Don't miss this opportunity to gain expert knowledge and network with industry leaders! Register now to secure your spot! * Agenda subject to change 💊 Only available for Senior Scientists and above, from Bio and Pharma companies with a drug pipeline. 💊 #OligonucleotideTherapeutics #BiotechEvents #PharmaceuticalManufacturing #BiotechLeadership #OligonucleotideDevelopment #DrugDevelopment #TherapeuticsInnovation #LifeSciences #BostonEvents #Biopharmaceuticals #NetworkingOpportunity #BioPharmaCommunity #hubXchange #Roundtable #FreePass #RegisterNow #ComplimentaryPass

The countdown is on—we’re less than three weeks away! ⏰ Join us for an exclusive webinar where we unpack recent research conducted by Tufts Center for the Study of Drug Development (CSDD), CluePoints, and PwC, shedding light on the current landscape of RBQM in pharmaceuticals, biotechnology, and CROs. During this session, Ken Getz of Tufts Center for the Study of Drug Development and Steve Young from CluePoints will deep-dive into our research findings, exploring not just where we stand today, but also where we’re heading tomorrow: https://bit.ly/4a71dxl #ClinicalResearch #RBQM #Pharma #Biotech

Subscribe to our Newsletter to stay up to date with OTS news! Simply scroll to the bottom of the page at oligotherapeutics.org/ to sign up and stay informed. #ots #oligotherapeutics #oligonucleotide #biotech #biotechnology #science #research #pharma #health #pharmaceuticals

Single Use Bioreactors Market worth $10.0 billion 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/dTvg9um2 The global single use bioreactors market is projected to reach USD 10.0 billion by 2028 from USD 4.2 billion in 2023, at a CAGR of 19.0% during the forecast period of 2023 to 2028. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. #SingleUse #bioreactors #Biomanufacturing #pharmaceutical #biopharmaceutical #biotechnology Sartorius Danaher Corporation Thermo Fisher Scientific Merck KGaA, Darmstadt, Germany Getinge Eppendorf Group Entegris Avantor Corning Incorporated Esco Kuhner shaker TECNIC PBS Biotech Satake Corporation G&G Technologies ABEC bbi-biotech GmbH REPROCELL Cellexus Distek, Inc. OmniBRx Biotechnologies Pvt Ltd New Horizon Biotech GPC Bio USA Meissner Cell Culture Company AUCTEQ Biosystems GmbH